Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

Table 3 Cohen’s d effect size estimates

Measure	n	Mean (SD) Change from Baseline	Cohen’s d
FACT/GOG-NTX*
Week 4	19	4.1 (0.2)	0.4
Week 9	19	10.9 (4.1)	1.4
Week 13	19	7.6 (1.2)	0.9
BPI-SF ^†
Worst pain
Week 4	18	2.4 (0.8)	0.8
Week 9	18	3.3 (1.4)	1.2
Week 13	18	2.6 (1.0)	0.9
Severity
Week 4	18	7.1 (3.4)	0.7
Week 9	18	10.6 (4.8)	1.1
Week 13	18	9.1 (4.0)	0.9
Interference
Week 4	18	7.2 (2.1)	0.4
Week 9	18	10.3 (4.0)	0.6
Week 13	18	7.8 (1.9)	0.5

*Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Scale.
^†Brief Pain Inventory – Short Form.

ISSN: 1756-8722